8-K: GeneDx Reports Q2 2026 Growth, Reaffirms Guidance

GeneDx Holdings Corp. announced its second quarter 2026 financial results, highlighting an 11% year-over-year revenue increase to $114.4 million and a 32% surge in exome and genome test volume.

Summary

• GeneDx Holdings Corp. reported second quarter 2026 revenue of $114.4 million, an 11% increase year-over-year.
• Exome and genome test revenue grew 17% year-over-year to $100.3 million.
• Exome and genome test volume increased by 32% year-over-year to 30,785 tests.
• Adjusted gross margin was 70%, slightly down from 71% in the prior year's quarter.
• Adjusted net income was $0.4 million, a significant decrease from $16.4 million in Q2 2025.
• GAAP net loss for the quarter was $17.7 million.
• The company reaffirmed its full-year 2026 revenue guidance of $475 to $490 million.
• Pro forma cash position after a recent financing is approximately $188 million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a cautiously optimistic report, with strong volume growth and reaffirmed guidance, but tempered by a return to adjusted net loss and a significant GAAP net loss.

Positives

• Strong year-over-year growth in exome and genome test volume (32%).
• Revenue increased by 11% year-over-year to $114.4 million.
• Exome and genome revenue saw a 17% year-over-year increase.
• Reaffirmed full-year 2026 revenue guidance of $475 to $490 million.
• Secured outpatient genome sequencing coverage from Carelon, a major lab benefit manager, potentially reaching 56 million covered lives.
• Expanded Medicaid coverage for genome sequencing in California and Mississippi.
• Pro forma cash position strengthened to approximately $188 million following a debt facility amendment and private placement.

Negatives

• Adjusted net income decreased significantly to $0.4 million from $16.4 million in the prior year's quarter.
• Reported a GAAP net loss of $17.7 million for the quarter.
• Adjusted gross margin slightly decreased to 70% from 71% in Q2 2025.
• Total GAAP operating expenses increased to $95.7 million.

Risks

• The highly competitive healthcare industry and changing regulatory landscape.
• The size and growth of the market in which the company operates.
• Future expansion of insurance coverage for exome and genome testing.
• Potential for downturns in the market.
• Risks and uncertainties detailed in the company's SEC filings, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Future Outlook

The company reaffirms its full-year 2026 revenue guidance of $475 to $490 million, with expectations for exome and genome volume growth of at least 30% and exome and genome revenue growth of at least 20%. Guidance for the third quarter of 2026 projects revenue between $122 to $124 million, exome and genome volume of 33,200 tests, and adjusted net income of approximately $2 million.

Management Comments

• "Our teams unwavering focus and agility drove a strong second quarter. By delivering healthy revenue, volume, and gross margin growth, we successfully navigated our return to profitability," said Katherine Stueland, CEO of GeneDx.
• "We are managing the transition to genome testing, making progress on each of our key imperatives – optimizing unit economics, growing utilization, and delivering the best products at unmatched scale – while continuing to extend our industry-leading position in both exome and genome testing to reach as many patients and families as soon as possible."

Industry Context

StockSavvy.ai notes that GeneDx's results reflect continued growth in the genomic testing market, driven by increasing insurance coverage and expanding clinical applications. The company's focus on exome and genome testing positions it within a high-growth segment of healthcare diagnostics, though competition and evolving reimbursement landscapes remain key factors.

Comparison to Industry Standards

• The reported adjusted gross margin of 70% is consistent with the company's historical performance and industry benchmarks for specialized diagnostic services, though slightly down from the prior year's quarter.
• The year-over-year volume growth of 32% in exome and genome testing outpaces general market growth for diagnostic tests, indicating strong market penetration and demand for GeneDx's specific offerings.
• The company's focus on expanding Medicaid and commercial payer coverage aligns with industry efforts to broaden access to advanced genetic diagnostics, a critical factor for sustained growth in the sector.

Legal Proceedings

• Costs related to legal reserves were incurred in the three months ended June 30, 2026.

Stakeholder Impact

• Shareholders: The company's financial performance, including its return to adjusted net loss and GAAP net loss, and its capital raise activities, will impact shareholder value. Reaffirmed guidance and strengthened cash position may be viewed positively.
• Customers (Patients and Clinicians): Continued expansion of coverage and product improvements aim to increase access to genomic diagnostics, benefiting patients and healthcare providers.
• Payers: Increased coverage for exome and genome testing, particularly with major payers like Carelon and expanded Medicaid programs, indicates a growing acceptance and integration of these services into healthcare systems.
• Creditors: The amendment to the loan agreement with Blackstone provides additional financial flexibility and liquidity.

Next Steps

• Continue to optimize unit economics.
• Grow utilization of exome and genome testing.
• Deliver the best products at unmatched scale.
• Extend industry-leading position in exome and genome testing.
• Roll out a broader suite of customer experience improvements.
• Expand coverage for exome and genome testing with additional payers and state Medicaid programs.
• Host a conference call to discuss Q2 2026 financial results.

Key Dates

Recommendation

The company shows strong volume growth and reaffirmed guidance, indicating operational strength and market demand. However, the significant drop in adjusted net income and the GAAP net loss, coupled with the need for additional capital, suggest caution. While the long-term potential in genomic diagnostics is high, the current financial performance warrants a 'hold' position until profitability trends improve and the impact of recent financing is fully assessed.

Keywords

GeneDx, genomic data, rare disease diagnosis, exome sequencing, genome sequencing, financial results, revenue guidance, Medicaid coverage